湘财证券则指出，当前正处于半年报密集披露期，从已披露年报来看，CRO公司受医药行业投融资下滑影响业绩普遍承压，但部分CRO公司对医药投融资情况改善比较乐观，据药石科技年报引用医药魔方的统计数据：2024年上半年全球创新药领域一级市场共发生412起融资事件，同比下降12.5％；从融资金额看，全球融资金额共151.61亿美元，同比上涨15.3%，海外创新药投资已逐步呈现抬头趋势。Stocks related to the CRO concept rose in the morning session. As of the press time, Wuxi Bio (02269) rose by 4.68% to HKD 10.74; Wuxi Apptec (02359) rose by 4.62% to HKD 32.85; Tigermed (03347) rose by 3.17% to HKD 29.3; Pharmaron (03759) rose by 2.48% to HKD 8.28.
According to the Zhitong Financial APP, stocks related to the CRO concept rose in the morning session. As of the press time, Wuxi Bio (02269) rose by 4.68% to HKD 10.74; Wuxi Apptec (02359) rose by 4.62% to HKD 32.85; Tigermed (03347) rose by 3.17% to HKD 29.3; Pharmaron (03759) rose by 2.48% to HKD 8.28.
GTJA stated that it is expected that the Federal Reserve will probably cut by 25 basis points in September, and it is highly likely that there will be 3 interest rate cuts this year. The current market's expectations of interest rate cuts are somewhat excessive. Powell's speech basically confirmed the shift in the Fed's monetary policy and the interest rate cut in September. However, there is still a significant game space for the magnitude and pace of the interest rate cut. Powell stated in his speech that he "will do everything possible to support a strong labor market while continuing to move towards the goal of price stability," which means that although there is an overall shift towards dovishness, inflation still needs to be considered. He also believes that the overall U.S. economy still has resilience and the speed of interest rate cuts may not be too fast.
Xiangcai Securities pointed out that we are currently in the midst of a period of intensive disclosure of semi-annual reports. From the disclosed annual reports, CRO companies have generally been under pressure due to the decline in pharmaceutical industry investment and financing. However, some CRO companies are relatively optimistic about changes in pharmaceutical investment and financing. According to statistics quoted from the Pharma Block Sciences annual report by Yaozhi, in the first half of 2024, there were a total of 412 financing events in the global innovative drug field, a decrease of 12.5% compared to the previous year. In terms of the financing amount, the total global financing amount was USD 15.161 billion, an increase of 15.3% compared to the previous year. Overseas investment in innovative drugs has gradually shown an upward trend.